OncoMatch/Clinical Trials/NCT04605913
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Is NCT04605913 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Modified GCN+TTF treatment for pancreas cancer.
Treatment: Modified GCN+TTF treatment — This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy for metastatic disease
Exception: prior neoadjuvant or adjuvant chemotherapy or chemo-radiotherapy allowed; gemcitabine-based adjuvant chemotherapy allowed if progression >6 months after completion; adjuvant FOLFIRINOX allowed if progression on therapy
Patients with no prior lines of therapy for the treatment of stage IV metastatic disease. Patients could have had prior neoadjuvant or adjuvant chemotherapy or chemo-radiotherapy. Patients who received gemcitabine-based adjuvant chemotherapy can enroll if they progress greater than 6 months after completion of the therapy; patients who progress while on adjuvant FOLFIRINOX can enroll immediately.
Lab requirements
Blood counts
ANC >1500/mm3; platelet count >100,000/mm3; hemoglobin >8 g/dL
Kidney function
serum creatinine WNL or creatinine clearance >50 mL/min
Liver function
Total bilirubin <1.5 x ULN; ALT or AST <3 x ULN (or <6 x ULN with liver metastases); total bilirubin <3 x ULN with liver metastases
Cardiac function
QTc ≤470 msec for men, ≤490 msec for women (Hodges' Equation); no 2nd/3rd degree heart block requiring pacemaker; no cardiac or abdominal pacemakers or stimulators; no significant risk of cardiac drug toxicity due to CHF or history of MI
Laboratory data as specified below: Hematology: ANC >1500 cells/mm3, platelet count >100,000 cells/mm3, Hemoglobin >8 g/dL. Hepatic: Total bilirubin <1.5 X ULN; ALT or AST <3 X ULN. For patients with known liver metastases or liver neoplasms: ALT or AST <6.0 X ULN and total bilirubin <3 x ULN. Renal: serum creatinine WNL or creatinine clearance >50 mL/min. QTc ≤470 msec for men and ≤490 msec for women. Cardiac conduction abnormalities such as 2nd and 3rd heart-block requiring a pacemaker [excluded]. Patient with cardiac or abdominal pacemakers or stimulators [excluded]. Significant risk of cardiac drug toxicity due to congestive heart failure or history of myocardial infarction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify